More importantly, our published studies demonstrated the safety of the plant extract in the Food and Drug Administration (FDA)-approved Phase I and II clinical trials in cancer patients through the use of our novel drug PBI-05204. [...]that is our current aim for PBI-05204. With respect to oleandrin and extracts containing this molecule, we point out that although toxicity can result in the use of high doses of this molecule, when used appropriately either for cancer or, as suggested, for treatment of certain viral-mediated diseases (including envelope viruses), the compound can be used with both safety and, we hope to prove, clinical efficacy.